Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Autor: Enrique Grande, A. Loehr, Petros Grivas, Dale L. Nepert, Yohann Loriot, Sumati Gupta, Daleen Thomas, Nicholas J. Vogelzang, Min Yuen Teo, Nabil Adra, Alejo Rodriguez-Vida, Rachel L. Dusek, Simon Chowdhury, S. Srinivas, Yousef Zakharia, Andrew Simmons, Andrea Necchi, Ajjai Alva, Susan Feyerabend, Kenton Wride, Rafael Morales-Barrera, Debra H. Josephs

Publikováno v: BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), pp.593. ⟨10.1186/s12885-021-08085-z⟩
BMC Cancer, 2021, 21 (1), pp.593. ⟨10.1186/s12885-021-08085-z⟩
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Scientia

BackgroundATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC).MethodsPatients with UC were enrolled independent of tumor hom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fd23d13c81759eb9e25d93f435c085c
https://doi.org/10.1186/s12885-021-08085-z

ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma

Autor: Petros Grivas, Andrew Simmons, Simon Chowdhury, Susan Feyerabend, Yousef Zakharia, Sandy Srinivas, Debra H. Josephs, Sumati Gupta, Alejo Rodriguez-Vida, Daleen Thomas, Kenton Wride, Y. Loriot, Dale L. Nepert, Rachel L. Dusek, Andrea Necchi

Publikováno v: European Urology Supplements. 18:e1838-e1839

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5bf0d8907c9709525f2d7909af9972b
https://doi.org/10.1016/s1569-9056(19)31331-4

ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC)

Autor: Petros Grivas, Nicholas J. Vogelzang, Ajjai Shivaram Alva, Susan Feyerabend, Yohann Loriot, Andrea Necchi, Sumati Gupta, Debra Hannah Josephs, Alejo Rodriguez-Vida, Sandy Srinivas, Yousef Zakharia, Kenton Wride, Daleen Thomas, Rachel Dusek, Andrew Simmons, Dale L. Nepert, Simon Chowdhury

Publikováno v: Journal of Clinical Oncology. 37:TPS496-TPS496

TPS496 Background: There are currently no standard treatment options for patients with mUC that has progressed on or after platinum (cisplatin/carboplatin)–based chemotherapy (PBC) and/or immune checkpoint inhibitors (ICIs), emphasizing the need fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83555bb65f1c483cc9c909aac39265ce
https://doi.org/10.1200/jco.2019.37.7_suppl.tps496

ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC)

Autor: Simon Chowdhury, Yohann Loriot, Petros Grivas, Daleen Thomas, Yousef Zakharia, Susan Feyerabend, Alejo Rodriguez-Vida, Rachel L. Dusek, Andrea Necchi, Andrew Simmons, Dale L. Nepert, Sumati Gupta, Ajjai Alva, Sandy Srinivas, Nicholas J. Vogelzang, Kenton Wride, Debra H. Josephs

Publikováno v: Journal of Clinical Oncology. 36:TPS4592-TPS4592

TPS4592Background: There are limited treatment options for pts with mUC that has progressed during or after platinum-based chemotherapy and/or immune checkpoint inhibitors (ICIs), emphasizing the n...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e3db8f6e19878df2b6c96395061f877
https://doi.org/10.1200/jco.2018.36.15_suppl.tps4592

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease

Autor: Dale L. Nepert, David R. Spigel, Margarita Majem, Fred J. Kudrik, Santiago Ponce, Mark A. Socinski, Peter M. Ellis, Paul Lorigan, Jesus Corral, Frederic J. Kaye, Leena Gandhi, Martin Gutierrez, Luis Gonzaga Paz Ares

Publikováno v: Clinical Lung Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Repisalud
Instituto de Salud Carlos III (ISCIII)
Socinski, M A, Kaye, F J, Spigel, D R, Kudrik, F J, Ponce, S, Ellis, P M, Majem, M, Lorigan, P, Gandhi, L, Gutierrez, M E, Nepert, D, Corral, J & Paz-Ares, L 2017, ' Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. ', Clinical Lung Cancer, vol. 18, no. 1, PMID: 2834110, pp. 68-76 . https://doi.org/10.1016/j.cllc.2016.09.002

Lorvotuzumab mertansine (LM, IMGN901) is a CD56-targeting antibody-drug conjugate developed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1/2 study evaluated the combination of LM with first-line carboplatin/etoposide che

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac929c5bd80dd3465fd3229718f3bad6
https://doi.org/10.1016/j.cllc.2016.09.002